A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine

被引：2
|
作者：
de Wet, Joseph J. [1 ,2 ]
Ban, Joann K. [3 ]
Verdier, Gustavo [4 ]
Ling, Juejing [5 ]
Eberg, Maria [5 ]
Bunko, Andrean [5 ]
McKimm, Michael [4 ,6 ]
机构：
[1] Spectrum Hlth, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Family Practice, Vancouver, BC, Canada
[3] GSK, Mississauga, ON, Canada
[4] ViiV Healthcare, Montreal, PQ, Canada
[5] IQVIA, Kirkland, PQ, Canada
[6] ViiV Healthcare, 75 Queen St,Suite 1400, Montreal, PQ H3C2N6, Canada
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2023年 / 62卷 / 02期
关键词：
D O I：
10.1016/j.ijantimicag.2023.106839
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China
    Yang, Xiaoyan
    Fu, Yanhua
    Xie, Xiaoxin
    Gan, Lin
    Song, Chunli
    Song, Yebing
    Li, Jun
    Long, Hai
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (11) : 1501 - 1508
  • [2] Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
    Rutherford, George W.
    Horvath, Hacsi
    PLOS ONE, 2016, 11 (10):
  • [3] Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study
    Palmier, E.
    De Miguel, R.
    Montejano, R.
    Busca, C.
    Mican, R.
    Ramos, L.
    Cadinanos, J.
    Serrano, L.
    Bernardino, J. I.
    Perez-Valero, I.
    Valencia, E.
    Arribas, J. R.
    Montes, M. L.
    Gonzalez-Garcia, J.
    Martin-Carbonero, L.
    HIV MEDICINE, 2023, 24 (09) : 1013 - 1019
  • [4] Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study
    Lagi, Filippo
    Giacomelli, Andrea
    Borghi, Vanni
    Ciccullo, Arturo
    Taramasso, Lucia
    Madeddu, Giordano
    D'Ettorre, Gabriella
    Giacometti, Andrea
    Ducci, Filippo
    De Vito, Andrea
    Pincino, Rachele
    Di Giambenedetto, Simona
    Mussini, Cristina
    Antinori, Spinello
    Sterrantino, Gaetana
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (10)
  • [5] Real-world comparative 48-week outcomes of switching to two nucleoside reverse transcriptase inhibitors and an integrase inhibitor
    Stegmann, K.
    Cassidy, S.
    Brydon, C.
    Barber, T.
    Smith, C.
    Swaden, L.
    Marshall, N.
    Burns, F.
    Taylor, S.
    Page, M.
    Farooq, H.
    Ustianowski, A.
    Reeves, I.
    Doctor, J.
    Simons, R.
    Larbalestier, N.
    Morris, S.
    Leen, C.
    Cairns, A.
    King, J.
    Kegg, S.
    Amlani, A.
    Simmons, K.
    Arenas, A.
    Taylor, C.
    Brook, G.
    Jagitsingh, G.
    Riddles, C.
    Friday, D.
    HIV MEDICINE, 2017, 18 : 18 - 18
  • [6] Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)
    Allavena, C.
    Volteau, C.
    Andre-Garnier, E.
    Guimard, T.
    Hall, N.
    Ithatchatourian, L.
    Morrier, M.
    Billaud, E.
    Rodallec, A.
    Reliquet, V.
    Jovelin, T.
    Le Guen, L.
    Perre, P.
    Gregoire, M.
    Raffi, F.
    MEDECINE ET MALADIES INFECTIEUSES, 2019, 49 (07): : 505 - 510
  • [7] Real-world use of dolutegravir/lamivudine in treatment-naive people living with HIV during the COVID pandemic
    Pierone, G., Jr.
    Fusco, J.
    Brunet, L.
    Vannappagari, V.
    Sarkar, S.
    Henegar, C.
    van Wyk, J.
    Zolopa, A.
    Fusco, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 60 - 60
  • [8] Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
    Bonfanti, Paolo
    De Vito, Andrea
    Ricci, Elena
    Menzaghi, Barbara
    Orofino, Giancarlo
    Squillace, Nicola
    Molteni, Chiara
    De Socio, Giuseppe Vittorio
    Salomoni, Elena
    Celesia, Benedetto Maurizio
    Dentone, Chiara
    Colombo, Valeria
    Madeddu, Giordano
    INFECTION AND DRUG RESISTANCE, 2020, 13 : 2291 - 2300
  • [9] 2-Year outcomes of dolutegravir plus lamivudine in ART-naive and pre-treated people living with HIV in Germany: Real-world Data From the URBAN Cohort
    Beer, Daniel
    Scherzer, Jenny
    Noe, Sebastian
    Scholten, Stefan
    Wyen, Christoph
    Postel, Nils
    Degen, Olaf
    Sabranski, Michael
    Westermayer, Bernd
    Dymek, Kathrin M.
    Baum, Alexander
    HIV MEDICINE, 2023, 24 : 28 - 30
  • [10] Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures
    Gagliardini, Roberta
    Lorenzini, Patrizia
    Cozzi-Lepri, Alessandro
    Tavelli, Alessandro
    Borghi, Vanni
    Galli, Laura
    Tagliaferri, Gianmarco
    Maggiolo, Franco
    Mussini, Cristina
    Castagna, Antonella
    Monforte, Antonella d'Arminio
    Antinori, Andrea
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 32 : 158 - 163
12345